Production Method 1

530115-96-9

948894-26-6

Reaction Conditions

1.1 Reagents: Hydrochloric acid Solvents: 1,4-Dioxane ;  16 h, rt

Reference

N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide derivatives and their use in the treatment of a CFTR-mediated disease

, World Intellectual Property Organization, , ,

Production Method 2

91419-52-2

948894-26-6

Reaction Conditions

1.1 Reagents: Lithium bis(trimethylsilyl)amide Solvents: Tetrahydrofuran ;  20 min, -78 °C
1.2 -78 °C; -78 °C → rt; 21 h, rt

Reference

Preparation of heterocyclic compounds as GPR40 agonists, regulating method for GPR40 receptors, and preventive and therapeutic methods for diabetes

, World Intellectual Property Organization, , ,

Production Method 3

530115-96-9

948894-26-6

Reaction Conditions

1.1 Reagents: Hydrochloric acid Solvents: Methanol ;  overnight, rt

Reference

Preparation of pyrrolopyrazine as kinase inhibitors useful for the treatment of autoimmune and inflammatory diseases

, United States, , ,

Production Method 4

530115-96-9

948894-26-6

948988-53-2

1257301-28-2

Reaction Conditions

1.1 Reagents: Hydrochloric acid Solvents: Acetonitrile ,  1,4-Dioxane ;  15 min, 70 °C

Reference

Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use as antitumor agents and manufacture

, World Intellectual Property Organization, , ,

Production Method 5

530115-96-9

948894-26-6

Reaction Conditions

1.1 Reagents: Hydrochloric acid Solvents: 1,4-Dioxane ;  1.5 h, rt

Reference

Preparation of phenylethanolamine derivatives, particularly 2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamines and 2-(4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl)ethylamines, as β2 adrenoreceptor agonists

, World Intellectual Property Organization, , ,

Production Method 6

530115-96-9

948894-26-6

1257301-28-2

Reaction Conditions

1.1 Reagents: Hydrochloric acid Solvents: Acetonitrile ,  1,4-Dioxane ;  15 min, 70 °C

Reference

Preparation of benzoxazepines as PI3K/mTOR inhibitors useful in the treatment of cancer

, World Intellectual Property Organization, , ,

Production Method 7

530115-96-9

948894-26-6

1257301-28-2

Reaction Conditions

1.1 Reagents: Hydrochloric acid Solvents: Acetonitrile ,  1,4-Dioxane ;  15 min, 70 °C

Reference

Preparation of benzoxazepine derivatives for use as mTOR inhibitors and useful in treatment of cancer

, World Intellectual Property Organization, , ,

Production Method 8

530115-96-9

948894-26-6

1257301-28-2

Reaction Conditions

1.1 Reagents: Hydrochloric acid Solvents: Acetonitrile ,  1,4-Dioxane ;  15 min, 70 °C

Reference

1,4-Benzoxazepine derivatives as PI3K and mTOR inhibitors and their preparation and use for the treatment of cancer

, World Intellectual Property Organization, , ,

4-Methylpiperidine-4-carbonitrile hydrochloride Raw materials

• tert-Butyl 4-cyano-4-methylpiperidine-1-carboxylate
• tert-butyl 4-cyanopiperidine-1-carboxylate

4-Methylpiperidine-4-carbonitrile hydrochloride Preparation Products

• 4-methylpiperidine-4-carbonitrile (948988-53-2)
• 4-Methyl-piperidine-4-carboxylic acid amide hydrochloride (1257301-28-2)
• 4-Methylpiperidine-4-carbonitrile hydrochloride (948894-26-6)

• 1. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 2. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 3. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 4. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 5. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549

Introduction to 4-Methylpiperidine-4-carbonitrile hydrochloride (CAS No. 948894-26-6)

4-Methylpiperidine-4-carbonitrile hydrochloride, identified by the Chemical Abstracts Service Number (CAS No.) 948894-26-6, is a significant compound in the realm of pharmaceutical chemistry and medicinal research. This compound belongs to the piperidine class, which is well-documented for its versatile applications in drug development due to its structural framework that can mimic biological targets effectively. The presence of a methyl group and a nitrile substituent at the 4-position of the piperidine ring introduces unique chemical properties that make it a valuable intermediate in synthesizing various pharmacologically active molecules.

The hydrochloride salt form of 4-methylpiperidine-4-carbonitrile enhances its solubility in aqueous solutions, making it more accessible for formulation and administration in biological assays. This property is particularly advantageous in drug discovery processes where solubility is a critical factor for bioavailability and efficacy. The compound’s stability under standard laboratory conditions further adds to its utility as a building block in synthetic chemistry.

In recent years, there has been growing interest in piperidine derivatives due to their role as key motifs in numerous therapeutic agents. For instance, compounds containing the piperidine scaffold have been explored in the development of antipsychotics, antivirals, and central nervous system (CNS) drugs. The nitrile group in 4-methylpiperidine-4-carbonitrile hydrochloride serves as a versatile handle for further functionalization, allowing chemists to introduce additional pharmacophores or modify existing ones to optimize biological activity.

One of the most compelling aspects of 4-methylpiperidine-4-carbonitrile hydrochloride is its potential application in the synthesis of small-molecule inhibitors targeting enzyme-driven diseases. Enzymes such as kinases and proteases often serve as critical nodes in cellular signaling pathways, and their inhibition can lead to therapeutic benefits. The piperidine ring can be incorporated into inhibitor molecules to enhance binding affinity and selectivity against these targets. Moreover, the nitrile group can participate in hydrogen bonding or other non-covalent interactions with residues in the enzyme active site, further improving drug-like properties.

Recent advancements in computational chemistry have enabled more efficient screening of compounds like 4-methylpiperidine-4-carbonitrile hydrochloride for their potential as drug candidates. Molecular docking studies have been employed to predict how this compound might interact with specific proteins, providing insights into its mechanism of action. These computational approaches complement traditional high-throughput screening methods, allowing researchers to prioritize promising candidates for experimental validation.

The pharmaceutical industry has also shown interest in 4-methylpiperidine-4-carbonitrile hydrochloride due to its potential role as an intermediate in producing novel therapeutics. For example, it has been investigated as a precursor for synthesizing compounds with anti-inflammatory or anticancer properties. The ability to modify the piperidine core while retaining the nitrile functionality offers chemists a high degree of flexibility in designing molecules with tailored biological activities.

Another area where 4-methylpiperidine-4-carbonitrile hydrochloride has found utility is in the development of vaccines and biologics. Piperidine derivatives have been incorporated into vaccine adjuvants and immunomodulators to enhance immune responses. The compound’s ability to interact with biological systems makes it a valuable tool for designing molecules that can modulate immune pathways effectively.

In conclusion, 4-methylpiperidine-4-carbonitrile hydrochloride (CAS No. 948894-26-6) represents a promising compound with diverse applications in pharmaceutical research and drug development. Its unique structural features, combined with its favorable physicochemical properties, make it an attractive candidate for further exploration. As research continues to uncover new therapeutic targets and synthetic strategies, compounds like this are likely to play an increasingly important role in addressing unmet medical needs.

• 1205749-97-8(3-methylpiperidine-3-carbonitrile;hydrochloride)
• 203662-67-3(7-azaspiro[3.5]nonane-2-carbonitrile)
• 948988-53-2(4-methylpiperidine-4-carbonitrile)
• 26458-78-6(4-Cyanoquinuclidine)
• 101756-36-9(Propanedinitrile,2-(1-methyl-4-piperidinylidene)-, hydrochloride (1:1))
• 20691-92-3(1-methylpiperidine-4-carbonitrile)
• 240401-22-3(Piperidine-4-carbonitrile hydrochloride)
• 62718-35-8(4-Piperidinecarbonitrile, 1,4-dimethyl-, hydrochloride (1:1))
• 62718-29-0(4-Piperidinecarbonitrile, 1,4-dimethyl-)
• 88654-16-4(4-Piperidinecarbonitrile, 1-ethyl-)